<DOC>
	<DOCNO>NCT00709488</DOCNO>
	<brief_summary>This phase 1 study evaluate safety effectiveness use Litx™ BPH System patient LUTS due benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Phase 1 Study Litx™ BPH System Patients With Lower Urinary Tract Symptoms ( LUTS ) Due Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description>The eligible patient enrol one three Litx™ treatment Cohorts ( A , B C ) All patient undergo procedure Litx™ BPH Device placement prostate urethra . Following placement Litx™ BPH Device urethra , patient Cohort A administered intravenous dose LS11 ( talaporfin sodium ) 1 mg/kg slow push 3 - 5 minute . Fifteen minute injection , patient administer 50 J total light dose , deliver 20 mW/cm 42 minute time period . Following placement Litx™ BPH Device urethra , patient Cohort B receive LS11 intravenously 1 mg/kg slow push 3 5 minute . The light activation procedure Cohort A except light dose 70 J deliver patient 58 minute time period . Following placement Litx™ BPH Device urethra , patient Cohort C receive LS11 intravenously 1 mg/kg slow push 3 5 minute . The light activation procedure Cohort A except light dose 100 J deliver patient 83 minute time period . Following placement Litx™ BPH Device urethra , patient Cohort D receive LS11 intravenously 1 mg/kg slow push 3 5 minute . The light activation procedure Cohort C except active light emit length 20 mm instead 10mm . After 30 day , patient experience improvement symptom , determine investigator , may undergo additional interventional therapy continue follow-up per protocol . Four week follow treatment last patient current cohort , number patient require surgical intervention relief primary symptom assess futility protocol prior commence treatment first patient next consecutive cohort . Upon acceptable safety assessment four week complete last patient treatment cohort , first patient next consecutive cohort may treat .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Talaporfin</mesh_term>
	<criteria>Males , 50 year old , alpha blocker and/or 5alpha reductase inhibitor combination , candidate interventional therapy . Patients continue alpha blocker and/or 5alpha reductase inhibitor least onemonth Litx™ treatment , tapered medication physician 's discretion . Patients understand ability sign write informed consent prior study procedure discontinuation exclusionary medication . Patients moderate severe BPH bother score &gt; 3 require nonmedication intervention . Patients IPSS1 Score &gt; 15 point . Maximum urinary flow rate ( Qmax ) ≤15 mL/sec . Post void residual volume ( PVR ) ≤300 mL . Prostatic volume &gt; 50g TRUS . Patients previous minimally invasive surgical intervention BPH . Patients enrol , currently enrol , another clinical trial disease within past 30 day . Patients active urinary tract infection . Patients urethral stricture . Patients predominant middle lobe obstruction . Patients evidence history prostate bladder cancer . Patients PSA &gt; 10 ng/ml . If PSA 410 ng/ml , preliminary biopsy do within oneyear prior entry study rule prostate cancer . Patients biopsy prostate within past 6 week . Patients bleed diathesis . Patients clinically significant renal hepatic impairment . Patients neurological condition felt affect bladder history neurogenic chronically decompensated bladder . Patients daily use pad device incontinence . Patients episode unstable angina pectoris , myocardial infarction , transient ischemic attack , cerebrovascular accident ( stroke ) within past 6 month , peripheral arterial disease intermittent claudication Leriches syndrome . Patient interest future fertility . Patients prolong QT interval baseline currently take medication prolong QT interval ( prolonged QT interval define &gt; 450 m ) . Inadequate organ function evidence follow : Platelet count &lt; 100,000/mm³ ; WBC &lt; 4,000/mm³ ; Neutrophils &lt; 1,800/mm³ ; Hemoglobin &lt; 10 g/dL ; SGOT SGPT &gt; 3 x ULN ; Creatinine &gt; 1.2 mg/dL Known sensitivity porphyrintype drug know history porphyria . Known sensitivity antibiotic ( i.e. , levofloxacin , gentamicin , etc. ) . Inability avoid sunlight procedure first 2 week LS11 administration .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Litx™ BPH System</keyword>
	<keyword>LS11</keyword>
	<keyword>Talaporfin sodium</keyword>
</DOC>